REG - Feedback PLC - Board Update

FeedbackAnnouncement

30/06/2021 15:35

RNS Number : 7086D
  
Feedback PLC
  
30 June 2021
  
 

Feedback plc
 
Board Update
 
 
London, 30 June 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that Simon Sturge has resigned as a Non-Executive Director of the Company to focus on his other commitments.
 
Rory Shaw, Chairman of Feedback, commented:
 
"We would like to thank Simon for his significant and valuable contributions over the past three years.  Simon has brought tremendous experience, guidance and insight to the Board and he leaves with Feedback in a stronger position than ever.  We wish him well for the future."
 
Simon Sturge, added:
 
"I have really enjoyed my time on the Board of Feedback and I believe that the Company is entering into a really exciting phase in its continued development."
 
 
Enquiries:
 




Feedback plc
Tom Oakley, CEO
 
Feedback media:
Nick Mayhew, Chief Marketing Lead


+44 (0)1954 718072
IR@fbk.com
 
 
+44 (0) 7736 065353




 


 




Allenby Capital Limited (Nominated Adviser)
David Worlidge / Vivek Bhardwaj


+44 (0)20 3328 5656




 


 




Peterhouse Capital Limited (Joint Broker)
Lucy Williams / Duncan Vasey


+44 (0)20 7469 0936




 


 




Stanford Capital Partners Limited (Joint Broker)
Patrick Claridge / John Howes


+44 20 3815 8880




 


 




Walbrook PR Ltd


Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 




Paul McManus/Nick Rome/Nicholas Johnson


07980 541 893 or 07748 325 236 or 07884 664 686




 
 
Notes to Editors
 
Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.  
 
Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAFLFFSRTIIVIL